146 related articles for article (PubMed ID: 34935484)
1. Engineering NK-92 Cell by Upregulating CXCR2 and IL-2 Via CRISPR-Cas9 Improves Its Antitumor Effects as Cellular Immunotherapy for Human Colon Cancer.
Gao L; Yang L; Zhang S; Ge Z; Su M; Shi Y; Wang X; Huang C
J Interferon Cytokine Res; 2021 Dec; 41(12):450-460. PubMed ID: 34935484
[TBL] [Abstract][Full Text] [Related]
2. Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma.
Kremer V; Ligtenberg MA; Zendehdel R; Seitz C; Duivenvoorden A; Wennerberg E; Colón E; Scherman-Plogell AH; Lundqvist A
J Immunother Cancer; 2017 Sep; 5(1):73. PubMed ID: 28923105
[TBL] [Abstract][Full Text] [Related]
3.
Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
[TBL] [Abstract][Full Text] [Related]
4. High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.
Clara JA; Levy ER; Reger R; Barisic S; Chen L; Cherkasova E; Chakraborty M; Allan DSJ; Childs R
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35135865
[TBL] [Abstract][Full Text] [Related]
5. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo.
Wennerberg E; Kremer V; Childs R; Lundqvist A
Cancer Immunol Immunother; 2015 Feb; 64(2):225-35. PubMed ID: 25344904
[TBL] [Abstract][Full Text] [Related]
6. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
[TBL] [Abstract][Full Text] [Related]
7. Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins.
Huang RS; Shih HA; Lai MC; Chang YJ; Lin S
Front Immunol; 2020; 11():1008. PubMed ID: 32528479
[TBL] [Abstract][Full Text] [Related]
8. Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9.
Afolabi LO; Adeshakin AO; Sani MM; Bi J; Wan X
Immunology; 2019 Oct; 158(2):63-69. PubMed ID: 31315144
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-Cas9-Mediated TIM3 Knockout in Human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells.
Morimoto T; Nakazawa T; Matsuda R; Nishimura F; Nakamura M; Yamada S; Nakagawa I; Park YS; Tsujimura T; Nakase H
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800561
[TBL] [Abstract][Full Text] [Related]
10. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo.
Nagashima S; Mailliard R; Kashii Y; Reichert TE; Herberman RB; Robbins P; Whiteside TL
Blood; 1998 May; 91(10):3850-61. PubMed ID: 9573023
[TBL] [Abstract][Full Text] [Related]
11. Genetical engineering for NK and T cell immunotherapy with CRISPR/Cas9 technology: Implications and challenges.
Zhi L; Su X; Yin M; Zhang Z; Lu H; Niu Z; Guo C; Zhu W; Zhang X
Cell Immunol; 2021 Nov; 369():104436. PubMed ID: 34500148
[TBL] [Abstract][Full Text] [Related]
12. Ex Vivo Expansion and CRISPR-Cas9 Genome Editing of Primary Human Natural Killer Cells.
Huang RS; Lai MC; Lin S
Curr Protoc; 2021 Sep; 1(9):e246. PubMed ID: 34529358
[TBL] [Abstract][Full Text] [Related]
13. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma.
Liu G; Rui W; Zheng H; Huang D; Yu F; Zhang Y; Dong J; Zhao X; Lin X
Eur J Immunol; 2020 May; 50(5):712-724. PubMed ID: 31981231
[TBL] [Abstract][Full Text] [Related]
14. A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy.
Pomeroy EJ; Hunzeker JT; Kluesner MG; Lahr WS; Smeester BA; Crosby MR; Lonetree CL; Yamamoto K; Bendzick L; Miller JS; Geller MA; Walcheck B; Felices M; Webber BR; Starr TK; Moriarity BS
Mol Ther; 2020 Jan; 28(1):52-63. PubMed ID: 31704085
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
16. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Ouji N; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
J Exp Clin Cancer Res; 2023 Aug; 42(1):205. PubMed ID: 37563692
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-Based Gene Engineering of Human Natural Killer Cells: Protocols for Knockout and Readouts to Evaluate Their Efficacy.
Lambert M; Leijonhufvud C; Segerberg F; Melenhorst JJ; Carlsten M
Methods Mol Biol; 2020; 2121():213-239. PubMed ID: 32147798
[TBL] [Abstract][Full Text] [Related]
18. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
19. Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells.
Gurney M; O'Reilly E; Corcoran S; Brophy S; Krawczyk J; Otto NM; Hermanson DL; Childs RW; Szegezdi E; O'Dwyer ME
Cytotherapy; 2022 Nov; 24(11):1087-1094. PubMed ID: 36050244
[TBL] [Abstract][Full Text] [Related]
20. Direct and indirect antitumor effects by human peripheral blood lymphocytes expressing both chimeric immune receptor and interleukin-2 in ovarian cancer xenograft model.
Lee JM; Yoon SH; Kim HS; Kim SY; Sohn HJ; Oh ST; Oh IH; Kim TG
Cancer Gene Ther; 2010 Oct; 17(10):742-50. PubMed ID: 20559334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
